The 5 most recent market catalysts affecting $GUTS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 85
Fractyl Health’s REMAIN-1 Study Meets Six-Month Co-Primary Endpoint With High Statistical Significance; Demonstrates 80% Retention Of GLP-1 Induced Weight Loss Vs 67% For Sham
Fractyl Health reported highly statistically significant positive six-month results from its REMAIN-1 study for the Revita DMR System. The study met its co-primary endpoint, demons…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (GUTS) announced its Q2 earnings, reporting a loss of $(0.16) per share, which was 23.08% wider than the analyst consensus estimate of $(0.13). This significant miss…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 85
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health (GUTS) announced compelling one-year results for its Revita DMR System, demonstrating its ability to significantly reduce weight regain after patients stop GLP-1 obe…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 85
Fractyl Health shares are trading higher after the company announced randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation.
This announcement is a significant corporate catalyst for Fractyl Health, as positive clinical trial data, especially demonstrating durable results after drug discontinuation, can …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.